What makes mucosal and anergic diffuse cutaneous leishmaniases so clinically and immunopathogically different? A review in Brazil

American cutaneous leishmaniasis (ACL) is a parasitic protozoan disease caused by different Leishmania species widely distributed throughout Latin America. Fifteen Leishmania species belonging to the subgenera Viannia, Leishmania and Mundinia are known to cause ACL. Seven of these species are found...

ver descrição completa

Detalhes bibliográficos
Autor: Silveira, Fernando Tobias
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2019
País:Brasil
Recursos:Instituto Evandro Chagas (IEC)
Repositório:Repositório Digital do Instituto Evandro Chagas (Patuá)
Idioma:inglês
OAI Identifier:oai:patua.iec.gov.br:iec/3970
Acesso em linha:https://patua.iec.gov.br/handle/iec/3970
Access Level:Acesso embargado
Palavra-chave:Leishmaniose Cutânea / parasitologia
Leishmaniose Mucocutânea / parasitologia
Leishmaniose Cutânea / imunologia
Leishmaniose Mucocutânea / imunologia
Pele / lesões
Revisão
Descrição
Resumo:American cutaneous leishmaniasis (ACL) is a parasitic protozoan disease caused by different Leishmania species widely distributed throughout Latin America. Fifteen Leishmania species belonging to the subgenera Viannia, Leishmania and Mundinia are known to cause ACL. Seven of these species are found in Brazil, of which Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis have the highest potential to cause mucosal (ML) and anergic diffuse cutaneous leishmaniasis (DCL), respectively, the most severe forms of ACL. The clinical and immunopathological differences between these two clinical forms are reviewed here, taking into account their different physiopathogenic mechanisms of dissemination from cutaneous lesions to mucosal tissues in the case of ML and to almost all body surfaces in the case of anergic DCL. We also discuss some immunopathogenic mechanisms of species-specific Leishmania antigens (from the subgenera Viannia and Leishmania) that are most likely associated with the clinical and immunopathological differences between ML and anergic DCL. Those discussions emphasize the pivotal importance of some surface antigens of L. (V.) braziliensis and L. (L.) amazonensis, such as lipophosphoglycan, phosphatidylserine and CD200 (an immunoregulatory molecule that inhibits macrophage activation), that have been shown to exert strong influences on the clinical and immunopathological differences between ML and anergic DCL.